to-BBB receives Frost & Sullivan Technology Innovation Award
CNS disorders are a major cause of mortality and debilitation. With increasing prevalence of neurodegenerative diseases and incidence of acute conditions like stroke, there is a need to develop effective therapies to tackle diseases with a CNS component. Frost & Sullivan recognizes that despite the growing understanding of CNS related diseases and the extensive efforts gone into developing molecules that target disease pathways, pharmaceutical and biotech companies still face the fundamental challenge of achieving effective delivery to the brain because of the presence of the neuroprotective blood-brain barrier.
In order to address the challenges of CNS targeted delivery, to-BBB has developed a technology platform (G-Technology®) that uniquely combines components that have already been extensively used in humans including a liposome-based drug delivery system and a targeting peptide ligand (glutathione).
The Frost & Sullivan Technology Innovation Award is a recognition of to-BBB’s accomplishments in the CNS Targeted Drug Delivery field. As an independent, third-party, Frost & Sullivan recognizes to-BBB for delivering excellence and best practices in this challenging field.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.